KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kiniksa Pharmaceuticals International, plc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$79.48+0.89 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $6.55B
- P/E (TTM)
- 88.3
- Dividend yield
- –
Kiniksa Pharmaceuticals International statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Market Cap | $12.40B | $197.05M |
| Enterprise Value | $11.93B | $106.56M |
| PE Ratio | 88.31 | 20.52 |
| PS Ratio | 16.45 | 3.93 |
| PB Ratio | 20.48 | 2.14 |
| P/TBV Ratio | 21.00 | 2.46 |
| P/FCF Ratio | 75.52 | 18.25 |
| P/OCF Ratio | 74.78 | 13.78 |
Enterprise value
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| EV / Sales | 15.83 | 2.69 |
| EV / EBITDA | 125.77 | 14.86 |
| EV / EBIT | 128.03 | 19.00 |
| EV / FCF | 72.67 | 21.02 |
Income (trailing twelve months)
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Revenue | $754.05M | $57.94M |
| Gross Profit | $673.44M | $90.47M |
| Operating Income | $93.22M | -$21.44M |
| Pretax Income | $105.98M | -$14.45M |
| Net Income | $73.06M | -$22.46M |
| EBITDA | $94.89M | -$16.91M |
| EPS (Diluted) | $0.90 | -$0.83 |
Margins
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Gross Margin | 89.3% | 52.3% |
| Operating Margin | 12.4% | -44.5% |
| Pretax Margin | 14.1% | -13.0% |
| Profit Margin | 9.69% | -39.2% |
| EBITDA Margin | 12.6% | -31.3% |
| FCF Margin | 21.8% | -8.85% |
Returns
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Return on Equity (ROE) | 13.7% | -53.1% |
| Return on Assets (ROA) | 10.3% | -41.0% |
| Return on Invested Capital (ROIC) | 39.3% | -32.0% |
| Return on Capital Employed (ROCE) | 13.9% | -37.8% |
Growth
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 56.7% | 6.01% |
| FCF Growth (YoY) | 275.5% | 2.34% |
| Revenue Growth (3Y CAGR) | 45.5% | 2.25% |
| EPS Growth (3Y CAGR) | -33.9% | -0.17% |
Balance sheet
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $468.09M | $62.42M |
| Net Cash (Debt) | $468.09M | $15.68M |
| Net Cash Per Share | $3.00 | $0.65 |
| Equity (Book Value) | $605.69M | $48.79M |
| Book Value Per Share | $3.88 | $1.36 |
| Tangible Book Value | $590.69M | $23.06M |
| Working Capital | $437.56M | $75.77M |
Financial position
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Current Ratio | 3.79 | 3.30 |
| Quick Ratio | 3.14 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Operating Cash Flow | $165.86M | -$12.35M |
| Capital Expenditures | -$1.63M | -$1.06M |
| Free Cash Flow | $164.23M | -$20.28M |
| FCF Per Share | $1.05 | -$0.41 |
Efficiency
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Asset Turnover | 1.06 | 0.38 |
| Inventory Turnover | 1.69 | 2.67 |
| Revenue Per Employee | $2.06M | $398.96K |
| Profits Per Employee | $199.61K | -$732.08K |
| Employee Count | 366 | 73 |
Dividends and yields
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Earnings Yield | 0.59% | -21.2% |
| FCF Yield | 1.32% | -7.64% |
Shares
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Shares Outstanding | 156,048,000 | 59,128,900 |
| Shares Change (YoY) | 10.7% | 11.1% |
| Float | 148,705,000 | 48,744,500 |
| Shares Held by Insiders | 4.71% | 11.8% |
Taxes
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Income Tax | $32.93M | $91.50K |
| Effective Tax Rate | 31.1% | 20.6% |
Scores
| Measure | Kiniksa Pharmaceuticals International | Industry median |
|---|---|---|
| Graham Number | $8.87 | $17.36 |
| Graham Upside | -88.8% | -45.5% |
| Altman Z-Score | 35.07 | 0.10 |
| Piotroski F-Score | 8 | 4 |
| Beneish M-Score | -3.16 | -2.62 |
Calculated by StockData from Kiniksa Pharmaceuticals International's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.